Cheam 510k Summary
JAN 1 6 2004
—.
= KOZSto| A of @
510(k) Summary
This 510(k) is to provide notification of substantial equivalence for the Candela Vbeam Pulse
Dye Laser System, which is substantially equivalent to previously marketed device intended for
photocoagulation of benign cutaneous vascular lesions, such as facial and leg telangiectasia,
rosacea, port wine stains, hemangiomas, angioma, spider angioma, Poikiloderma of Civatee and
benign cutaneous lesions, such as warts, scars, striea and psoriasis. Photocoagulation of benign
cutaneous lesion and benign vascular lesion in Gynecology, treatment of wrinkles and the
treatment of inflammatory acne vulgaris. There have been no modifications to design to the
Vbeam Pulse Dye Laser as cleared under K 021180.
Submitted by: Candela Corporation
530 Boston Post Road
Wayland, MA 01778-1886
Contact Person: Lorraine Calzetta
Date prepared: October 10, 2003
Classification: Class H (21 CFR § 878.4810 Laser Surgical Instrument for use
in General and Plastic Surgery and in Dermatology)
Common Name: Dermatology Laser, Vbeam Pulse Dye Laser System
Predicate Devices: Candela Vbeam Pulse Dye Laser (K021180), ICN Photonics
NLite (K024189)
Description:
The Vbeam is a 595 nm flash-lamp excited pulse dye medical laser, controlled by an embedded
microprocessor., to be used for the treatment of benign cutaneous vascular lesions, such as facial
and leg telangiectasia, rosacea, port wine stains, hemangiomas, angioma, spider angioma,
Poikiloderma of Civatee and benign cutaneous lesions, such as warts, scars, striea and psoriasis.
Photocoagulation of benign cutaneous lesion and benign vascular lesion in Gynecology, for the
treatment of wrinkles and the treatment of inflammatory acne vulgaris.. The Vbeam laser may be
used with the Candela Dynamic Cooling Device, which provides a short burst of cryogen spray
prior to firing the laser pulse. The laser output energy is delivered via an optical fiber to a
handpiece, which produces circular beams with diameters of 5, 7 or 10 millimeters on the skin.
The cryogen, which is housed within the laser enclosure, is delivered via a hose to a nozzle
located in the handpiece.
The Candela Vbeam Pulse Dye Laser is equipped with safety interlock systems to protect
patients and operators. Users of the device make selections from an onboard contro} panel to
regulate operation during treatment.
o
8 O02

Cbeam 510k Summary
é K0 334] Aq 2
Asa laser product, the Vbeam Pulsed Dye Laser is required to conform and does conform to the
Laser Performance Standard (21 CFR 1040). In addition the Cbeam conforms to the UL 2601
Electrical Safety Standard and with the Harmonized Standard EN 60601-1-2, Part 2 established
by and required by the European Community.
Summary of Substantial Equivalence:
The Candela Vbeam Laser has the same intended use, utilizes similar operating principles and
matches key design aspects, including similar spot size, and maximum delivered power as the
predicate device.
On the basis of similarities in methods of assembly, method of operation, and intended uses,
Candela Corporation believes that its Candela Vbeam Laser System is substantially equivalent to
the predicate device.

ame,
i DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
‘ Cc
ve Food and Drug Administration
9200 Corporate Boulevard
‘JAN 1 6 2004 Rockville MD 20850
Ms. Lorraine Calzetta Patrovic
Manger, Regulatory Affairs
Candela Corporation
530 Boston Post Road
Wayland, Massachusetts 01778
Re: K033461
Trade/Device Name: Candela Vbeam Pulse Dye Laser System
Regulation Number: 21 CFR 878.4810
Regulation Name: Laser surgical instrument for use in general and
plastic surgery and in dermatology
Regulatory Class: II
Product Code: GEX
Dated: October 27, 2003
Received: October 30, 2003
Dear Ms. Patrovic:
We have reviewed your Section 510(k) premarkct notification of intent to market the device
referenced above and have determined the device is substantially equivalent (for the indications
for use stated in the enclosure) to legally marketed predicate devices marketed in interstate
commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to
devices that have been reclassified in accordance with the provisions of the Federal I’ood, Drug,
and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).
You may, therefore, market the device, subject to the general controls provisions of the Act. The
general controls provisions of the Act include requirements for annual registration, listing of
devices, good manufacturing practice, labeling, and prohibitions against misbranding and
adulteration.
If your device is classified (see above) into either class II (Special Controls) or class I] (PMA), it
may be subject to such additional controls. Existing major regulations affecting your device can
be found in the Code of Fedcral Regulations, Title 21, Parts 800 to 898. In addition, FOA may
publish further announcements concerning your device in the Federal Register.
Please be advised that FDA’s issuance of a substantial equivalence determination does not mean
that FDA has made a determination that your device complics with other requirements of the Act
or any Federal statutes and regulations administered by other Federal agencies. You must
comply with all the Act’s requirements, including, but not limited to: registration and listing (21
CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic
product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 - Ms. Lorraine Calzetta Patrovic
This letter will allow you to begin marketing your device as described in your Section 510(k)
premarket notification, The FDA finding of substantial equivalence of your device to a legally
marketed predicate device results in a classification for your dévice and thus, permits your device
to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please
contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled,
"Misbranding by reference to premarket notification” (21CFR Part 807.97). You may obtain
other general information on your responsibilities under the Act from the Division of Small
Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or
(301) 443-6597 or at its Internet address http:/Awww.fda.gov/edrh/dsma/dsmamain, htm!

Sincerely yours,

Muuane C. Vent

 Cotia M. Witten, Ph.D., M.D.
Director
Division of General, Restorative
and Neurological Devices

Office of Device Evaluation

Center for Devices and Radiological Health
Enclosure :

Indications for Use
510(k) Number (if known): _K0334614
Device Name: Candela Vbeam Pulse Dye Laser System
Indications For Use:
The Candela Vbeam Pulse Dye Laser is indicated for the following uses in:
General Surgery: Photocoagulation of benign cutaneous vascular lesion and benign cutaneous
lesions.
Dermatology/Plastic Surgery: For treatment of benign cutaneous vascular lesion, such as facial
and leg telangiectasia, rosacea, port wine stains, hemangiomas, angioma, spider angioma,
Poikiloderma of Civatte, and benign cutaneous lesions, such as warts, scars, striae and
psoriasis. and the treatment of wrinkles. :
New indication : Treatment of Inflammatory Acne Vulgaris
Gynecology: Photocoagulation of benign cutaneous lesion and benign vascular lesion in
gynecology.
Podiatry: Treatment of benign cutaneous lesion, such as warts.
Prescription Use _X AND/OR Over-The-Counter Use
(Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF
NEEDED)
. ev
Concurrence of CDRH, Office of Device Evaluation (ODE)
ran © Erovroat

(Division Sign-Off) Page 1 of |

Division of General, Restorative

and Neurological Devices

oon) Number. XO3346l

